Recurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report

被引:1
作者
Jia-Min Li [1 ]
Han Chen [1 ]
机构
[1] Department of Cardiology, Zhejiang Provincial Key Laboratory of Cardiovascular Disease Diagnosis and Treatment, The Second Affiliated Hospital, Zhejiang University School of Medicine
关键词
Sacubitril/valsartan; Duchenne muscular dystrophy; Heart failure; Hypotension; Case report;
D O I
暂无
中图分类号
R746.2 [肌营养不良症]; R725.4 [小儿心脏、血管疾病];
学科分类号
1002 ; 100202 ;
摘要
BACKGROUND Duchenne muscular dystrophy(DMD), which is caused by a mutation/deletion in the dystrophin gene on the X-chromosome, is the most common type of neuromuscular disorder in pediatrics. Skeletal muscle weakness progressively develops in DMD patients and usually leads to respiratory failure in the early adolescent years. Cardiac muscle is frequently affected in DMD patients, which leads to a high burden of cardiomyopathy and heart failure. In the era of improved respiratory care, cardiac deaths are becoming the major cause of mortality in DMD patients.CASE SUMMARY We report the case of a 15-year-old boy who presented to the hospital due to recurrent orthopnea for 6 mo and palpitations for 4 mo. He was diagnosed with progressive muscular dystrophy at the age of 3 years and was confined to a wheelchair at 12 years. He was prescribed diuretics and digoxin at the outpatient clinic; however, his symptoms did not resolve. Sacubitril/valsartan was added 1 mo prior to presentation, but he experienced recurrent episodes of palpitations.The electrocardiogram showed atrial tachycardia with a heart rate of 201 bpm,and he was then hospitalized. Hypotension was found following the administration of sacubitril/valsartan tablets; he could not tolerate even a small dose, always developing tachyarrhythmia. His symptoms were relieved after discontinuing sacubitril/valsartan, and his heart rate was controlled by a small dose of metoprolol tartrate and digoxin. Atrial tachycardia spontaneously converted in this patient, and his symptoms attenuated in the following 6 mo,without palpitation episodes.CONCLUSION Blood pressure should be closely monitored in DMD patients with advanced heart failure when taking sacubitril/valsartan.
引用
收藏
页码:4098 / 4105
页数:8
相关论文
共 11 条
[1]  
Sacubitril–valsartan in heart failure and multimorbidity patients[J] . Raquel Rodil Fraile,Vincenzo Malafarina,Gregorio Tiberio López.ESC Heart Failure . 2018 (5)
[2]  
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction[J] . Kieran F. Docherty,John J.V. McMurray.International Journal of Cardiology . 2018
[3]  
Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock[J] . H. A. Rawal,A. G. Kocheril,Tayfun Sahin.Case Reports in Cardiology . 2018
[4]  
Sacubitril/valsartan and short-term changes in the 6-minute walk test: A pilot study[J] . Paola Beltrán,Patricia Palau,Eloy Domínguez,Mercedes Faraudo,Eduardo Nú?ez,Olga Guri,Anna Mollar,Juan Sanchis,Antoni Bayés-Genís,Julio Nú?ez.International Journal of Cardiology . 2018
[5]   A current approach to heart failure in Duchenne muscular dystrophy [J].
D'Amario, Domenico ;
Amodeo, Antonio ;
Adorisio, Rachele ;
Tiziano, Francesco Danilo ;
Leone, Antonio Maria ;
Perri, Gianluigi ;
Bruno, Piergiorgio ;
Massetti, Massimo ;
Ferlini, Alessandra ;
Pane, Marika ;
Niccoli, Giampaolo ;
Porto, Italo ;
D'Angelo, Gianluca A. ;
Borovac, Josip Andelo ;
Mercuri, Eugenio ;
Crea, Filippo .
HEART, 2017, 103 (22) :1770-+
[6]  
Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy[J] . Daniel Cheeran MD,Shaida Khan MD,Rohan Khera MD,Anish Bhatt MD,Sonia Garg MD,MEng,Justin L. Grodin MD,MPH,Robert Morlend MD,Faris G. Araj MD,Alpesh A. Amin MD,Jennifer T. Thibodeau MD,MSc,Sandeep Das MD,MPH,Mark H. Drazner MD,MSc,Pradeep P. A. Mammen MD.Journal of the American Heart Association . 2017 (10)
[7]   Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects [J].
Krittanawong, Chayakrit ;
Kitai, Takeshi .
CARDIOVASCULAR THERAPEUTICS, 2017, 35 (04)
[8]  
Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy[J] . Abdallah Fayssoil,Soumeth Abasse,Katy Silverston.Journal of Neuromuscular Diseases . 2017 (1)
[9]  
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure[J] . John J.V. McMurray,Milton Packer,Akshay S. Desai,Jianjian Gong,Martin P. Lefkowitz,Adel R. Rizkala,Jean L. Rouleau,Victor C. Shi,Scott D. Solomon,Karl Swedberg,Michael R. Zile.The New England Journal of Medicine . 2014 (11)
[10]  
Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy[J] . Hitoko Ogata,Yuka Ishikawa,Yukitoshi Ishikawa,Ryoji Minami.Journal of Cardiology . 2008 (1)